US 11,896,615 B2
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
Michael Ports, Seattle, WA (US); Evan Paul Thomas, Seattle, WA (US); and Hyam I. Levitsky, Seattle, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Appl. No. 16/340,085
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
PCT Filed Oct. 13, 2017, PCT No. PCT/US2017/056680
§ 371(c)(1), (2) Date Apr. 5, 2019,
PCT Pub. No. WO2018/071873, PCT Pub. Date Apr. 19, 2018.
Claims priority of provisional application 62/514,767, filed on Jun. 2, 2017.
Claims priority of provisional application 62/407,776, filed on Oct. 13, 2016.
Prior Publication US 2020/0054673 A1, Feb. 20, 2020
Int. Cl. C12N 5/07 (2010.01); A61K 35/17 (2015.01); A61K 31/4245 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/90 (2006.01); G01N 33/574 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 31/4245 (2013.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C12N 15/907 (2013.01); G01N 33/57496 (2013.01); C07K 2319/03 (2013.01); C12N 2310/20 (2017.05)] 22 Claims
 
1. A method of treatment of cancer in a subject in need thereof, comprising:
(a) administering a T cell therapy to the subject having cancer; and
(b) administering to the subject a therapeutically effective amount of an inhibitor of indoleamine-pyrrole 2,3-dioxygenase 1 (IDO1) subsequent to the initiation of administration of the T cell therapy,
wherein the T cell therapy comprises an engineered T cell comprising a recombinant receptor that specifically binds to an antigen, wherein the recombinant receptor is a chimeric antigen receptor (CAR) or a transgenic T cell receptor (TCR),
wherein the inhibitor of IDO1 is administered within 14 days subsequent to the initiation of the T cell therapy,
wherein, prior to the administration of the T cell therapy, the subject has not been administered an IDO inhibitor for treatment of cancer, and
wherein the cancer comprises a tumor comprising cells negative for IDO1 prior to the initiation of administration of the T cell therapy.